Enrollment In Phase III studies with Nexavar in patients with metastatic melanoma and liver cancer Completed – Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals today announced the completion of patient enrollment in two randomized, double-blind – blind, phase III clinical trials, a Nexavar tablets in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced metastatic melanoma and other Nexavar as single agent in patients with advanced hepatocellular carcinoma , or liver cancer read more .
Forward-Looking StatementsThis press release contains forward-looking on current assumptions on current assumptions and forecasts made Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here lead. A more detailed descriptionese factors include those described in Bayer’s public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission . Bayer assumes no liability whatsoever to update these forward-looking – conform them to future events or developments.
People who from may suffer from a sleeping disorder encouraging by her doctor, the consult to an to a sleep specialist. The abortion had the highest among female aged between 19 on 35 per 1,000 according to the figures there 3.4 million to contraception formation, in London Telegraph reports (Davies, Telegraph.